drugset

drugset / Trial / NCT06577077

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

NCT06577077 ↗

Phase 3 Not yet recruiting 432 enrolled Ache Laboratorios Farmaceuticos S.A.

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of CM9241GRU versus placebo in the treatment of perennial allergic rhinitis.

Timeline

Start: 2024-09
Primary completion: 2025-08
Completion: 2025-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM9241GRU	Unknown	1 unknown	—

Indications